The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
12.3 clinical trial regulation
Clinical trials regulation
News round up
The European Parliament has now approved by large majority the new clinical trials regulation as agreed at trilogue with the European Commission and Member State Governments. See EU Monitor article here.
Abbvie has now dropped its court case against the European Medicines Agency (EMA) on transparent reporting of trial results. More information here
Boehringer have announced they will publish trial data going back to 1998. More information here.
Meanwhile recent news about Roche and Tamiflu has heightened awareness of the need for transparency in the area of medicines research. More information here.
EMA liaison
The EMA has now invited EAHP to take part in a stakeholder conference call in early May on how they take forward their proposals for publishing more information about trial results. More information here. FV is available to participate and represent EAHP.
TTIP concerns
Fears are being raised that current negotiations between the EU and the USA on a trade agreement (TTIP) could threaten some of the gains made. More information here and here.
The Board Meeting provides an opportunity to discuss and agree any next steps in EAHP advocacy on this topic.